Dr. Amit Oza is a Senior Staff Physician and Professor of Medicine at the Princess Margaret Cancer Centre and the University of Toronto. He is cross-appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew's Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in UK. He completed Clinical Research Fellowships at St. Bartholomew's Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Hospital, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin's Disease. He is a Fellow of the Royal College of Physicians of London and Canada.
Dr. Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynecological cancer and advanced colorectal malignancies. His research interests are focused towards the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMH.
Dr. Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.
He is currently interim Head, Department of Medical Oncology & Hematology, Co-Director of the Robert and Maggie Bras and Family Drug Development Program at the Princess Margaret Cancer Centre. This is the largest new drug development program in Canada and the only center outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is Co-Chair for the Gynecological Cancer Steering Committee of the National Cancer Institute and represents the Princess Margaret Phase II Consortium at the Gynecologic Cancer InterGroup.